|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 203 EUR | -3.20% |
|
+3.31% | -15.24% |
| Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
| Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sartorius Stedim Biotech S.A. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 666.9 million compared to EUR 726.1 million a year ago. Net income was EUR 56.1 million compared to EUR 111.1 million a year ago.
Basic earnings per share from continuing operations was EUR 0.58 compared to EUR 1.21 a year ago. Diluted earnings per share from continuing operations was EUR 0.58 compared to EUR 1.21 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.24% | 21.86B | |
| -3.72% | 186B | |
| -2.60% | 107B | |
| -3.79% | 67.44B | |
| +2.66% | 50.03B | |
| +16.39% | 47.81B | |
| +4.68% | 41.03B | |
| +1.38% | 26.85B | |
| +1.52% | 25.82B | |
| -1.17% | 25.01B |
SARTORIUS STEDIM BIOTECH 
